Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
2006. g. dec. · John Wiley & Sons
E-grāmata
391
Lappuses
reportAtsauksmes un vērtējumi nav pārbaudīti. Uzzināt vairāk
Par šo e-grāmatu
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Par autoru
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Novērtējiet šo e-grāmatu
Izsakiet savu viedokli!
Informācija lasīšanai
Viedtālruņi un planšetdatori
Instalējiet lietotni Google Play grāmatas Android ierīcēm un iPad planšetdatoriem/iPhone tālruņiem. Lietotne tiks automātiski sinhronizēta ar jūsu kontu un ļaus lasīt saturu tiešsaistē vai bezsaistē neatkarīgi no jūsu atrašanās vietas.
Klēpjdatori un galddatori
Varat klausīties pakalpojumā Google Play iegādātās audiogrāmatas, izmantojot datora tīmekļa pārlūkprogrammu.
E-lasītāji un citas ierīces
Lai lasītu grāmatas tādās elektroniskās tintes ierīcēs kā Kobo e-lasītāji, nepieciešams lejupielādēt failu un pārsūtīt to uz savu ierīci. Izpildiet palīdzības centrā sniegtos detalizētos norādījumus, lai pārsūtītu failus uz atbalstītiem e-lasītājiem.
